Upside factor: 1) Further progress on second hospital in China, which could be in Shenzhen or other top cities. Shenzhen hospital first announced in Feb 2013.
2) Faster-than-expected breakeven for Singapore expansion. Normal breakeven period is one year.
3) Medical tourism in Singapore could recover from 2015
weakness as RFMD is constantly seeking new source
markets.
Downside factor: 1) Execution risks for Shanghai hospital, its first outside Singapore.
2) Higher-than-expected start-up costs in major expansion markets such as China.
3) Structural decline of medical tourism in Singapore
Upside factor: 1) Further progress on second hospital in China, which could be in Shenzhen or other top cities. Shenzhen hospital first announced in Feb 2013.
2) Faster-than-expected breakeven for Singapore expansion. Normal breakeven period is one year.
3) Medical tourism in Singapore could recover from 2015
weakness as RFMD is constantly seeking new source
markets.